Article By:
Benzinga
Sunday, February 7, 2021 5:00 PM EDT
Biopharma stocks advanced in the week ended Feb. 5, driven higher by a slew of catalysts. Large-cap pharma earnings, vaccine updates, M&A activity, IPO news flow, and follow-on offerings all served to lift stocks higher.
Intercept Downgraded To Sell From Neutral At H.C. Wainwright
Does this matter? They upgraded one of my stocks last week $ABEO to a price that is 3 times the price then and it went down so hard since then. Screw the Anal-ysts.